Home / Health / mRNA Cancer Vaccine Prevents Skin Cancer Recurrence
mRNA Cancer Vaccine Prevents Skin Cancer Recurrence
19 Aug
Summary
- An experimental mRNA drug prevented skin cancer recurrence in a large trial.
- This is the first mRNA cancer drug to successfully complete a Phase 3 trial.
- The treatment combines an mRNA vaccine with immunotherapy drug Keytruda.
An experimental drug utilizing messenger RNA technology has demonstrated significant success in preventing skin cancer recurrence during a large-scale clinical trial. This development marks a pivotal moment, as it is the first mRNA-based cancer treatment to successfully navigate a Phase 3 trial.
The drug, intismeran, targets melanoma, the most aggressive form of skin cancer. In combination with the immunotherapy Keytruda, it has shown a substantial reduction in the risk of recurrence or death for patients with resected melanoma.
This innovative treatment involves sequencing a patient's tumor to identify unique mutations. An algorithm then selects key mutations for an mRNA vaccine, which instructs the patient's immune system to attack the cancer cells. Keytruda assists by enhancing the immune response.
The success of this trial is anticipated to establish a new paradigm for cancer treatment, with similar mRNA therapies being investigated for other cancers like lung, kidney, and bladder. Longer follow-up studies are necessary to confirm the sustained efficacy of the treatment.
